Imatinib Grindeks (Imatinib)

Imatinib blocks the ATP‑binding sites of BCR‑ABL, c‑KIT and PDGFR tyrosine kinases. By preventing phosphorylation of downstream signaling proteins, it stops the proliferative and survival signals that cancer cells rely on, leading to reduced tumor growth and increased apoptosis of the malignant cells.

The specific dose of Imatinib Grindeks is determined by the prescribing clinician based on the patient’s diagnosis, disease stage, body weight, renal and hepatic function, and other individual factors. Only a qualified healthcare professional should set the dosing regimen.

Imatinib is classified as contraindicated or not recommended during pregnancy because it may cause fetal harm. Breastfeeding is also discouraged, as the drug can be excreted in milk. Women of child‑bearing potential should discuss contraception and alternative therapies with their physician.

To place an order, submit an enquiry on the Imatinib Grindeks product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Imatinib was the first BCR‑ABL inhibitor and remains a standard of care for CML and Ph+ ALL. Compared with newer agents such as dasatinib or nilotinib, it has a well‑characterized safety profile and fewer drug‑drug interactions, though some patients may require a second‑generation inhibitor for resistant disease.

Imatinib Grindeks should be stored at room temperature, below 25 °C, in its original packaging. The container protects the product from moisture and light, helping to maintain potency throughout its shelf life.

The medication is taken orally, usually as a whole tablet swallowed with water. It can be taken with or without food, but patients should follow the specific instructions provided by their healthcare professional to ensure consistent absorption.

Serious adverse events include severe neutropenia, hepatotoxicity, cardiac failure, and rare cases of interstitial lung disease. Patients should be monitored regularly for blood‑count changes, liver function abnormalities, and signs of cardiac dysfunction, and any concerning symptoms should be reported promptly.

Imatinib is contraindicated in individuals with known hypersensitivity to the drug or any of its excipients. It should also be avoided in patients with severe hepatic impairment, uncontrolled cardiac disease, or in pregnant women unless the benefits clearly outweigh the risks.